Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
OraSure Technologies's 3-Year RORE % for the quarter that ended in Mar. 2026 was 116.37%.
The industry rank for OraSure Technologies's 3-Year RORE % or its related term are showing as below:
FRA:EP3's 3-Year RORE % is ranked better than 92.96% of 781
companies
in the Medical Devices & Instruments industry
Industry Median: -4.19
vs FRA:EP3: 116.37
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
OraSure Technologies 3-Year RORE % Related Terms
OraSure Technologies 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for OraSure Technologies's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EP3 vs UTMD, SMTI, EMBC: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, OraSure Technologies's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OraSure Technologies 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OraSure Technologies's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where OraSure Technologies's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
OraSure Technologies (FRA:EP3) has a 3-Year RORE % of 116.37 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on OraSure Technologies and its competitors. According to the industry distribution chart, OraSure Technologies ranks #55 out of 781 companies in the Medical Devices & Instruments industry, placing it in the top 7%.
Is OraSure Technologies' 3-Year RORE % too high?
OraSure Technologies' current 3-Year RORE % is 116.37. Based on the distribution chart, OraSure Technologies ranks #55 out of 781 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, OraSure Technologies has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OraSure Technologies' 3-Year RORE % compare to UTMD and SMTI?
According to the Medical Devices & Instruments industry distribution chart, OraSure Technologies ranks #55 out of 781 companies for 3-Year RORE %. This places OraSure Technologies in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on OraSure Technologies and its competitors. OraSure Technologies's current 3-Year RORE % is 116.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OraSure Technologies stock overvalued right now?
Based on GuruFocus' analysis, OraSure Technologies (FRA:EP3) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.72, compared to a current price of €3.68 — trading 114% above its estimated fair value. The current 3-Year RORE % is 116.37. OraSure Technologies' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For OraSure Technologies (FRA:EP3), the current 3-Year RORE % is 116.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OraSure Technologies (FRA:EP3) Overvalued in 2026?
Based on GuruFocus' analysis, OraSure Technologies stock appears to be overvalued.
The current stock price of €3.68 is trading 114% above its estimated GF Value™ of €1.72.
GuruFocus considers OraSure Technologies to be Significantly Overvalued.
Key valuation signals for FRA:EP3:
3-Year RORE %: 116.37
GF Value™: €1.72 vs. price of €3.68 (114% above fair value)
No single metric tells the full story. See the FRA:EP3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.
51GF Score
Get the complete analysis for FRA:EP3
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EP3 has been successfully added to your 
